Medicus Pharma Files EU Submission for $4B Teverelix Phase 2b in High-Risk Prostate Cancer
MDCX•Medicus Pharma has filed a substantial modification application with the EU CTIS to support its planned 2026 Phase 2b study of Teverelix® in high cardiovascular-risk advanced prostate cancer patients, representing a ~$4 billion annual market opportunity. The study will optimize dose selection and characterize Teverelix’s rapid, flare-free testosterone suppression and long-acting depot profile ahead of registrational development.
1. EU Regulatory Submission
Medicus Pharma submitted a substantial modification application through the European Union Clinical Trials Information System to enable the planned Phase 2b study of Teverelix® in advanced prostate cancer patients with elevated cardiovascular risk. This submission marks a key milestone in the company’s strategy to advance Teverelix toward registrational development in Europe and the United States.
2. Phase 2b Study Design
The Phase 2b trial is structured to optimize dose selection while further characterizing pharmacokinetic, pharmacodynamic, efficacy and safety profiles of Teverelix®. Patient enrollment is expected to begin later this year, with data intended to inform registrational study design and future regulatory discussions.
3. Teverelix Differentiated Profile
Teverelix® is a long-acting GnRH antagonist designed for rapid, flare-free testosterone suppression and profound follicle-stimulating hormone inhibition via a convenient depot formulation. These pharmacologic characteristics may offer meaningful advantages over traditional GnRH agonists, especially for patients where cardiovascular outcomes are a primary concern.
4. Market Opportunity and Next Steps
Advanced prostate cancer patients with elevated cardiovascular risk represent an estimated $4 billion annual market across major regions. Subject to regulatory authorization, the company aims to leverage Phase 2b data to finalize registrational planning and position Teverelix® as a best-in-class hormonal therapy for this underserved patient population.
